Onconova Therapeutics (ONTX) Receives a Rating Update from a Top Analyst


In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Onconova Therapeutics (ONTX), with a price target of $2.00. The company’s shares closed last Monday at $1.19.

According to TipRanks.com, Pantginis is a top 100 analyst with an average return of 30.5% and a 54.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Onconova Therapeutics with a $1.52 average price target.

See today’s analyst top recommended stocks >>

Based on Onconova Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $52K and GAAP net loss of $5.09 million. In comparison, last year the company earned revenue of $68K and had a GAAP net loss of $7.6 million.

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ONTX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Read More on ONTX:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts